Observational studyBMC nephrology2025
Dilemma of missing specific disease codes: an approach to assess the incidence and prevalence of a rare nephrology disease.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEstimating disease epidemiology using health insurance claims data is challenging due to the lack of specific diagnostic codes. This study demonstrates an approach to estimate the epidemiology of primary immunoglobulin A nephropathy (IgAN) using German Statutory Health Insurance (SHI) claims data.
methodsA retrospective observational study was conducted using data from January 1
resultsThe mean prevalence rate from 2017-2022 ranged from 4.5 (restrictive codes) to 38.3 (inclusive codes) cases per 100,000 individuals, demonstrating the orphan nature of primary IgAN. Mean incidence rates ranged from 0.2 to 0.6 cases per 100,000 individuals. In 2022, this corresponded to an estimated 4,043 to 32,229 prevalent cases and 164 to 538 incident cases in Germany.
conclusionThis study presents an approach for estimating disease epidemiology in the absence of specific diagnostic codes, using primary IgAN as an example. While our dual-algorithm method provides valuable insights into the incidence and prevalence of primary IgAN in Germany, it also highlights the need for consistent coding practices and specific diagnostic codes for accurate epidemiological assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.